H. Kawachi, M. Tamiya, Yuko Oya, G. Saito, Yoshihiko Taniguchi, H. Matsumoto, Yuki Sato, Taiichiro Otsuki, H. Suzuki, Yasushi Fukuda, Satoshi Tanaka, Y. Tsukita, Junji Uchida, Y. Sakata, Yuki Nakatani, R. Shibaki, Daisuke Arai, A. Okada, Satoshi Hara, Koichi Takayama, K. Nishino
{"title":"局部晚期非小细胞肺癌化放疗和Durvalumab巩固治疗进展后后续化疗的实际效果:CRIMSON研究(HOPE-005)的探索性分析","authors":"H. Kawachi, M. Tamiya, Yuko Oya, G. Saito, Yoshihiko Taniguchi, H. Matsumoto, Yuki Sato, Taiichiro Otsuki, H. Suzuki, Yasushi Fukuda, Satoshi Tanaka, Y. Tsukita, Junji Uchida, Y. Sakata, Yuki Nakatani, R. Shibaki, Daisuke Arai, A. Okada, Satoshi Hara, Koichi Takayama, K. Nishino","doi":"10.1016/j.cllc.2024.07.014","DOIUrl":null,"url":null,"abstract":"","PeriodicalId":504941,"journal":{"name":"Clinical Lung Cancer","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005)\",\"authors\":\"H. Kawachi, M. Tamiya, Yuko Oya, G. Saito, Yoshihiko Taniguchi, H. Matsumoto, Yuki Sato, Taiichiro Otsuki, H. Suzuki, Yasushi Fukuda, Satoshi Tanaka, Y. Tsukita, Junji Uchida, Y. Sakata, Yuki Nakatani, R. Shibaki, Daisuke Arai, A. Okada, Satoshi Hara, Koichi Takayama, K. Nishino\",\"doi\":\"10.1016/j.cllc.2024.07.014\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"\",\"PeriodicalId\":504941,\"journal\":{\"name\":\"Clinical Lung Cancer\",\"volume\":null,\"pages\":null},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2024-07-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Lung Cancer\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1016/j.cllc.2024.07.014\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Lung Cancer","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1016/j.cllc.2024.07.014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Real-World Outcomes of Subsequent Chemotherapy after Progression Following Chemoradiation and Consolidative Durvalumab Therapy in Locally Advanced Non-Small Cell Lung Cancer: An Exploratory Analysis from the CRIMSON Study (HOPE-005)